Putaala Jukka, Martinez-Majander Nicolas, Saeed Sahrai, Yesilot Nilufer, Jäkälä Pekka, Nerg Ossi, Tsivgoulis Georgios, Numminen Heikki, Gordin Daniel, von Sarnowski Bettina, Waje-Andreassen Ulrike, Ylikotila Pauli, Roine Risto O, Zedde Marialuisa, Huhtakangas Juha, Fonseca Catarina, Redfors Petra, de Leeuw Frank-Erik, Pezzini Alessandro, Kõrv Janika, Schneider Siim, Tanislav Christian, Enzinger Christian, Jatuzis Dalius, Siegerink Bob, Martínez-Sánchez Patricia, Grau Armin J, Palm Frederick, Groop Per-Henrik, Lanthier Sylvain, Ten Cate Hugo, Pussinen Pirkko, Paju Susanna, Sinisalo Juha, Lehto Mika, Lindgren Arne, Ferro José, Kittner Steven, Fazekas Franz, Gerdts Eva, Tatlisumak Turgut
Department of Neurology, Helsinki University Hospital, Finland.
Department of Clinical Science, University of Bergen, Norway.
Eur Stroke J. 2017 Jun;2(2):116-125. doi: 10.1177/2396987317703210. Epub 2017 Apr 4.
Worldwide, about 1.3 million annual ischaemic strokes (IS) occur in adults aged <50 years. Of these early-onset strokes, up to 50% can be regarded as cryptogenic or associated with conditions with poorly documented causality like patent foramen ovale and coagulopathies.
KEY HYPOTHESES/AIMS: (1) Investigate transient triggers and clinical/sub-clinical chronic risk factors associated with cryptogenic IS in the young; (2) use cardiac imaging methods exceeding state-of-the-art to reveal novel sources for embolism; (3) search for covert thrombosis and haemostasis abnormalities; (4) discover new disease pathways using next-generation sequencing and RNA gene expression studies; (5) determine patient prognosis by use of phenotypic and genetic data; and (6) adapt systems medicine approach to investigate complex risk-factor interactions.
Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome (SECRETO; NCT01934725) is a prospective multi-centre case-control study enrolling patients aged 18-49 years hospitalised due to first-ever imaging-proven IS of undetermined etiology. Patients are examined according to a standardised protocol and followed up for 10 years. Patients are 1:1 age- and sex-matched to stroke-free controls. Key study elements include centralised reading of echocardiography, electrocardiography, and neurovascular imaging, as well as blood samples for genetic, gene-expression, thrombosis and haemostasis and biomarker analysis. We aim to have 600 patient-control pairs enrolled by the end of 2018.
SECRETO is aiming to establish novel mechanisms and prognosis of cryptogenic IS in the young and will provide new directions for therapy development for these patients. First results are anticipated in 2019.
在全球范围内,每年约有130万例缺血性卒中(IS)发生在50岁以下的成年人中。在这些早发性卒中中,高达50%可被视为隐源性卒中,或与因果关系记录不佳的情况相关,如卵圆孔未闭和凝血病。
关键假设/目标:(1)研究与年轻人隐源性IS相关的短暂触发因素和临床/亚临床慢性风险因素;(2)使用超越现有技术水平的心脏成像方法来揭示新的栓塞来源;(3)寻找隐匿性血栓形成和止血异常;(4)利用下一代测序和RNA基因表达研究发现新的疾病途径;(5)通过使用表型和基因数据确定患者预后;(6)采用系统医学方法研究复杂的风险因素相互作用。
《寻找年轻人隐源性卒中的解释:揭示病因、触发因素和结局》(SECRETO;NCT01934725)是一项前瞻性多中心病例对照研究,纳入因首次影像学证实的病因不明的IS而住院的18 - 49岁患者。患者按照标准化方案进行检查,并随访10年。患者与无卒中的对照按1:1进行年龄和性别匹配。关键研究内容包括对超声心动图、心电图和神经血管成像进行集中解读,以及采集血液样本进行基因、基因表达、血栓形成、止血和生物标志物分析。我们的目标是到2018年底招募600对患者 - 对照。
SECRETO旨在确立年轻人隐源性IS的新机制和预后,并将为这些患者的治疗发展提供新方向。预计2019年得出初步结果。